journal article·2016

Maghemite-human serum albumin hybrid nanoparticles: towards a theranostic system with high MRI r 2 * relaxivity

Rivka Ben Ishay, Liron L. Israel, Esthy Levy Eitan, David M. Partouche, Jean-Paul Lellouche

Journal of Materials Chemistry B· Volume 4· Issue 21
Publisher page

Abstract

Human Serum Albumin (HSA) is the most abundant plasma protein in human blood, and therefore, it is the material of choice for the development of particulate formulations due to its biodegradable and biocompatible nature. Over the last decade, HSA nanoparticles (NPs) have been prepared mostly using desolvation techniques and evaluated as promising drug carriers. In addition, controlling the particle size has become a primary concern while formulating such nanoparticulate systems. Since many of these HSA-based carrier systems have often demonstrated batch-to-batch fabrication variability, significant efforts have been made to develop and characterize HSA-based NPs featuring a robust and controllable particle size, by using a desolvation/cross-linking-type Divinyl Sulfone (DVS)-mediated nanofabrication method. For this purpose and for global multi-parameter fabrication process optimization, a statistically significant Design of Experiment (DoE, MINITAB® 17 DoE software) methodology has been successfully implemented. It aimed to disclose an optimal set of HSA NP fabrication conditions in order to afford highly reproducible and stable 23.05 ± 5.3 nm-sized DoE-globally optimized core HSA NPs. Due to the use of bifunctional DVS as a cross-linker for the preparation of such DoE-optimized HSA NPs, their surface contains a variety of free functional groups which are available for further second step functional modifications. Moreover, related hybrid organic/inorganic nanosystems consisting of DoE-optimized HSA NPs that encapsulated hydrophilic (NH4)2Ce(IV)(NO3)6 (Ceric Ammonium Nitrate - CAN) modified γ-Fe2O3 NPs (CAN-maghemite or CAN-γ-Fe2O3 NPs), which enable medical imaging using magnetic resonance imaging (MRI), have also been fabricated and characterized. The resulting hybrid magnetic NPs are a quite powerful T2* contrast agent (r2* of 482 mM-1 s-1), which may be used as a powerful dual phase platform for both therapeutic (drug delivery) and diagnostic imaging (MRI) applications.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Lanthanide and Transition Metal Complexes · Protein Interaction Studies and Fluorescence Analysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry

Nanomaterials Research Center

Institute of Nanotechnology & Advanced Materials

Bar-Ilan University

Ramat-Gan 5290002

References (48)

Show source-provided references
1. Rubino · Pharm. Res. · 1993 · 10 · 105910.1023/A:1018979126326 ↗
2. Rahimnejad · Afr. J. Biotechnol. · 2006 · 5 · 1918
3. Kratz · J. Controlled Release · 2008 · 132 · 17110.1016/j.jconrel.2008.05.010 ↗
4. Neumann · Expert Opin. Drug Delivery · 2010 · 7 · 91510.1517/17425247.2010.498474 ↗
5. Stehle · Anticancer Drugs · 1999 · 10 · 78510.1097/00001813-199909000-00012 ↗
6. Zhang · Huaxue Jinzhan · 2011 · 23 · 1747
7. Hirose · Mater. Sci. Eng., C · 2010 · 30 · 66410.1016/j.msec.2010.02.020 ↗
8. Elzoghby · J. Controlled Release · 2012 · 157 · 16810.1016/j.jconrel.2011.07.031 ↗
9. Wartlick · J. Drug Targeting · 2004 · 12 · 46110.1080/10611860400010697 ↗
10. Steinhauser · Biomaterials · 2008 · 29 · 402210.1016/j.biomaterials.2008.07.001 ↗
11. Ulbrich · Eur. J. Pharm. Biopharm. · 2009 · 71 · 25110.1016/j.ejpb.2008.08.021 ↗
12. Geny · J. Am. Coll. Cardiol. · 1993 · 22 · 119310.1016/0735-1097(93)90437-6 ↗
13. Ibrahim · Clin. Cancer Res. · 2002 · 8 · 1038
14. Brzoska · Biochem. Biophys. Res. Commun. · 2004 · 318 · 56210.1016/j.bbrc.2004.04.067 ↗
15. Langer · Int. J. Pharm. · 2003 · 257 · 16910.1016/S0378-5173(03)00134-0 ↗
16. Weber · Int. J. Pharm. · 2000 · 194 · 9110.1016/S0378-5173(99)00370-1 ↗
17. Patil · Drug Dev. Res. · 2003 · 58 · 21910.1002/ddr.10157 ↗
18. Yu · Biopolymers · 2006 · 83 · 14810.1002/bip.20539 ↗
19. Lee · Int. J. Pharm. · 2011 · 403 · 19210.1016/j.ijpharm.2010.10.012 ↗
20. N. Desai , Drug Delivery Report Winter 2007/2008, 37–41
21. Xu · Bioconjugate Chem. · 2011 · 22 · 87010.1021/bc1002295 ↗
22. Ford-Moore · J. Chem. Soc. · 1949 · 243310.1039/jr9490002433 ↗
23. Morpurgo · Bioconjugate Chem. · 1996 · 7 · 36310.1021/bc9600224 ↗
24. Friedman · J. Org. Chem. · 1966 · 31 · 288810.1021/jo01347a036 ↗
25. Houen · J. Immunol. Methods · 1995 · 181 · 18710.1016/0022-1759(94)00345-W ↗
26. Kailasam · Chemosphere · 2007 · 66 · 16510.1016/j.chemosphere.2006.05.035 ↗
27. Sarin · Anal. Biochem. · 1981 · 117 · 14710.1016/0003-2697(81)90704-1 ↗
28. Adair · ACS Nano · 2010 · 4 · 496710.1021/nn102324e ↗
29. Israel · J. Mater. Chem. B · 2014 · 2 · 621510.1039/C4TB00634H ↗
30. Ferrari · Nat. Nano · 2008 · 3 · 13110.1038/nnano.2008.46 ↗
31. Cawse · Acc. Chem. Res. · 2001 · 34 · 21310.1021/ar000117s ↗
32. Lendrem · Org. Process Res. Dev. · 2001 · 5 · 32410.1021/op000025i ↗
33. McKay · Curr. Opin. Drug Discovery Dev. · 2003 · 6 · 966
34. R. Kenett , S.Zacks and D.Amberti, Modern Industrial Statistics: with applications in R, MINITAB and JMP, John Wiley & Sons, 201310.1002/9781118763667 ↗
35. Shin · Chem. Soc. Rev. · 2015 · 44 · 450110.1039/C4CS00345D ↗
36. Zensi · J. Controlled Release · 2009 · 137 · 7810.1016/j.jconrel.2009.03.002 ↗
37. Korkusuz · Molecular Imaging and Biology · 2012 · 15 · 14810.1007/s11307-012-0579-6 ↗
38. Wang · Quantitative Imaging in Medicine and Surgery · 2011 · 1 · 35
39. Wahajuddin · Int. J. Nanomed. · 2012 · 7 · 344510.2147/IJN.S30320 ↗
40. England · Mol. Pharmaceutics · 2016 · 13 · 810.1021/acs.molpharmaceut.5b00626 ↗
41. Zhou · Nat. Commun. · 2015 · 6 · 798410.1038/ncomms8984 ↗
42. Xie · Biomaterials · 2010 · 31 · 301610.1016/j.biomaterials.2010.01.010 ↗
43. Roch · J. Magn. Magn. Mater. · 2005 · 293 · 53210.1016/j.jmmm.2005.01.070 ↗
44. Huang · Theranostics · 2012 · 2 · 8610.7150/thno.4006 ↗
45. Vuong · Adv. Healthcare Mater. · 2012 · 1 · 50210.1002/adhm.201200078 ↗
46. Rosenberger · J. Controlled Release · 2014 · 194 · 13010.1016/j.jconrel.2014.08.017 ↗
47. Rosenberger · J. Controlled Release · 2015 · 214 · 7610.1016/j.jconrel.2015.07.017 ↗
48. Liron · Mater. Res. Express · 2015 · 2 · 09500910.1088/2053-1591/2/9/095009 ↗